Many Intra-Cellular Therapies Inc.(ITCI) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. ITI Inc was Initiated by Cantor Fitzgerald to Overweight on Dec 16, 2016.
Company has reported several Insider transactions to the SEC, on Jan 9, 2017, Kimberly E. Vanover (SVP, Clinical Development) sold 800 shares at 16.59 per share price.On Jan 9, 2017, Sharon Mates (Chairman, President & CEO) sold 4,081 shares at 16.55 per share price.On Jan 9, 2017, Lawrence J. Hineline (VP of Finance CFO) sold 1,918 shares at 16.58 per share price.
ITI Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.17. Analyst had a consensus of $-0.87. The company had revenue of $4.36 million for the quarter, compared to analysts expectations of $.04 million. During the same quarter in the previous year, the company posted $-0.91 EPS.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 5 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 2 Brokerage Firms have advised hold.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares are expected to touch $26.25 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 8.69. The target price could hit $37 on the higher end and $17 on the lower end.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) rose 2.71% or 0.36 points on Tuesday and made its way into the gainers of the day. After trading began at $13.2 the stock was seen hitting $13.73 as a peak level and $13.19 as the lowest level. The stock ended up at $13.63. The daily volume was measured at 600,677 shares. The 52-week high of the share price is $45.2 and the 52-week low is $10.8. The company has a market cap of $590 million.
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.